New combo therapy aims to boost platelet counts in ITP patients
NCT ID NCT07315373
First seen Jan 05, 2026 · Last updated May 15, 2026 · Updated 15 times
Summary
This study tests different doses of zanubrutinib combined with high-dose dexamethasone in 60 adults newly diagnosed with immune thrombocytopenia (ITP), a condition causing low platelet counts and bleeding. The goal is to find the safest and most effective dose to raise platelet levels and reduce bleeding. Participants will be monitored for 26 weeks to see if their platelet counts stay stable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.